Background:Most (70%–100%) ovarian carcinomas express high levels of the epidermal growth factor receptor (EGFR). To examine the relationship between EGFR and the invasive phenotype, we assessed integrin expression, adhesion, matrix metalloproteinase (MMP) activity, and migration in ovarian cancer cells in which EGFR expression was modified. Meth-ods: NIH:OVCAR-8 human ovarian carcinoma cells were transfected with an expression vector containing the human EGFR complementary DNA in an antisense orientation (EGFR-antisense cells) or the vector alone (vector control cells). We compared vector control and EGFR-antisense cells for cell morphology and adhesion by light microscopy, expression of 6- and 3-integrin subunits by flow cytom-etry, MMP a...
Advanced ovarian cancer carries a grim prognosis and development of targeted therapies to improve ou...
Epithelial ovarian carcinoma is a deadly disease, and little is known about the mechanisms underlyin...
Background: The progress in basic ovarian cancer research has been slow, mainly because of the lack ...
Ovarian cancer is the third most leading type of cancer among women in India. The major drawback of ...
The overexpression of epidermal growth factor receptor (EGFR) has been shown in ovarian cancer and i...
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that regulates various c...
Ovarian cancer is the primary cause of death from gynecological malignancies with a poor prognosis c...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
The epidermal growth factor receptor is overexpressed in up to 60% of ovarian epithelial malignancie...
Objectives. The EGFR is expressed in malignant ovarian tumor tissue, and tissue content of EGFR has ...
Background: Epithelial ovarian cancer often develops resis-tance to standard treatments, which is a ...
Background: Although antiestrogens have been effective in preventing estrogen receptor (ER)-positive...
Abstract: Background: Ras homolog gene family member A (RhoA) is involved in Wnt-5a–induced migratio...
Cisplatin (DDP) is the most effective drug for the treatment of human ovarian cancer, but the mechan...
P(論文)Tumor cells always interact with host reactive cells in the process of carcinogenesis and tumor...
Advanced ovarian cancer carries a grim prognosis and development of targeted therapies to improve ou...
Epithelial ovarian carcinoma is a deadly disease, and little is known about the mechanisms underlyin...
Background: The progress in basic ovarian cancer research has been slow, mainly because of the lack ...
Ovarian cancer is the third most leading type of cancer among women in India. The major drawback of ...
The overexpression of epidermal growth factor receptor (EGFR) has been shown in ovarian cancer and i...
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that regulates various c...
Ovarian cancer is the primary cause of death from gynecological malignancies with a poor prognosis c...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
The epidermal growth factor receptor is overexpressed in up to 60% of ovarian epithelial malignancie...
Objectives. The EGFR is expressed in malignant ovarian tumor tissue, and tissue content of EGFR has ...
Background: Epithelial ovarian cancer often develops resis-tance to standard treatments, which is a ...
Background: Although antiestrogens have been effective in preventing estrogen receptor (ER)-positive...
Abstract: Background: Ras homolog gene family member A (RhoA) is involved in Wnt-5a–induced migratio...
Cisplatin (DDP) is the most effective drug for the treatment of human ovarian cancer, but the mechan...
P(論文)Tumor cells always interact with host reactive cells in the process of carcinogenesis and tumor...
Advanced ovarian cancer carries a grim prognosis and development of targeted therapies to improve ou...
Epithelial ovarian carcinoma is a deadly disease, and little is known about the mechanisms underlyin...
Background: The progress in basic ovarian cancer research has been slow, mainly because of the lack ...